| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hospitals, Veterans | 36 | 2021 | 359 | 5.340 |
Why?
|
| Patient Protection and Affordable Care Act | 10 | 2024 | 64 | 5.280 |
Why?
|
| Medicaid | 10 | 2024 | 243 | 4.810 |
Why?
|
| United States Department of Veterans Affairs | 43 | 2024 | 671 | 4.650 |
Why?
|
| Reimbursement, Incentive | 14 | 2018 | 47 | 4.320 |
Why?
|
| Quality of Health Care | 21 | 2022 | 391 | 3.950 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 29 | 2023 | 728 | 3.520 |
Why?
|
| Veterans | 30 | 2024 | 1757 | 3.120 |
Why?
|
| Cardiovascular Diseases | 32 | 2023 | 1911 | 3.120 |
Why?
|
| Primary Health Care | 22 | 2022 | 774 | 3.030 |
Why?
|
| United States | 113 | 2024 | 10821 | 2.880 |
Why?
|
| Veterans Health | 10 | 2023 | 176 | 2.780 |
Why?
|
| Quality Indicators, Health Care | 12 | 2024 | 218 | 2.680 |
Why?
|
| Delivery of Health Care | 14 | 2023 | 606 | 2.620 |
Why?
|
| Nursing Staff, Hospital | 4 | 2024 | 59 | 2.570 |
Why?
|
| Hypertension | 19 | 2021 | 1289 | 2.550 |
Why?
|
| Quality Assurance, Health Care | 7 | 2021 | 206 | 2.440 |
Why?
|
| Atherosclerosis | 20 | 2023 | 849 | 2.310 |
Why?
|
| Cholesterol, LDL | 13 | 2021 | 560 | 2.100 |
Why?
|
| Hospitals | 8 | 2024 | 398 | 2.060 |
Why?
|
| Health Services Research | 19 | 2020 | 188 | 1.920 |
Why?
|
| Medical Records Systems, Computerized | 11 | 2010 | 166 | 1.880 |
Why?
|
| Guideline Adherence | 20 | 2019 | 380 | 1.870 |
Why?
|
| Patient Care Team | 9 | 2019 | 547 | 1.840 |
Why?
|
| Workload | 3 | 2024 | 148 | 1.640 |
Why?
|
| Politics | 3 | 2023 | 58 | 1.630 |
Why?
|
| Ambulatory Care | 7 | 2022 | 387 | 1.620 |
Why?
|
| Physicians | 6 | 2017 | 581 | 1.600 |
Why?
|
| Diabetes Mellitus | 15 | 2021 | 859 | 1.590 |
Why?
|
| Coronary Disease | 9 | 2020 | 655 | 1.510 |
Why?
|
| Humans | 204 | 2025 | 124481 | 1.510 |
Why?
|
| Health Services Accessibility | 16 | 2023 | 606 | 1.500 |
Why?
|
| Personnel Staffing and Scheduling | 5 | 2024 | 78 | 1.470 |
Why?
|
| Aged | 87 | 2025 | 19549 | 1.350 |
Why?
|
| Intensive Care Units, Neonatal | 8 | 2014 | 319 | 1.340 |
Why?
|
| Physician Incentive Plans | 5 | 2017 | 13 | 1.310 |
Why?
|
| Coronary Artery Disease | 9 | 2022 | 760 | 1.300 |
Why?
|
| Nurse Practitioners | 4 | 2021 | 46 | 1.290 |
Why?
|
| Patient Acceptance of Health Care | 6 | 2020 | 422 | 1.290 |
Why?
|
| Middle Aged | 85 | 2025 | 26511 | 1.260 |
Why?
|
| Physician Assistants | 4 | 2021 | 68 | 1.260 |
Why?
|
| Medication Adherence | 12 | 2021 | 400 | 1.250 |
Why?
|
| Practice Patterns, Physicians' | 16 | 2020 | 723 | 1.230 |
Why?
|
| Insurance Coverage | 4 | 2024 | 121 | 1.180 |
Why?
|
| Physicians, Primary Care | 6 | 2021 | 94 | 1.170 |
Why?
|
| Male | 116 | 2024 | 61053 | 1.160 |
Why?
|
| Risk Adjustment | 7 | 2021 | 59 | 1.130 |
Why?
|
| Hypolipidemic Agents | 4 | 2019 | 179 | 1.120 |
Why?
|
| Medicare | 10 | 2023 | 424 | 1.110 |
Why?
|
| Diagnostic Errors | 7 | 2011 | 332 | 1.080 |
Why?
|
| Female | 108 | 2025 | 66318 | 1.070 |
Why?
|
| Myocardial Infarction | 12 | 2020 | 1017 | 1.060 |
Why?
|
| Lipids | 6 | 2019 | 512 | 1.060 |
Why?
|
| State Government | 2 | 2023 | 29 | 1.030 |
Why?
|
| Quality Improvement | 7 | 2024 | 636 | 1.020 |
Why?
|
| Outpatient Clinics, Hospital | 5 | 2013 | 72 | 0.960 |
Why?
|
| Continuity of Patient Care | 6 | 2018 | 154 | 0.940 |
Why?
|
| Practice Guidelines as Topic | 16 | 2019 | 1261 | 0.910 |
Why?
|
| Cholesterol | 9 | 2019 | 531 | 0.910 |
Why?
|
| Nursing Research | 1 | 2024 | 11 | 0.890 |
Why?
|
| Infant, Very Low Birth Weight | 4 | 2014 | 170 | 0.880 |
Why?
|
| Poverty | 3 | 2024 | 418 | 0.860 |
Why?
|
| Logistic Models | 18 | 2020 | 1807 | 0.860 |
Why?
|
| Dyslipidemias | 7 | 2020 | 227 | 0.820 |
Why?
|
| Research Design | 4 | 2021 | 690 | 0.820 |
Why?
|
| Peer Review, Health Care | 2 | 2013 | 17 | 0.820 |
Why?
|
| User-Computer Interface | 2 | 2023 | 155 | 0.810 |
Why?
|
| Hypercholesterolemia | 6 | 2019 | 227 | 0.810 |
Why?
|
| Mortality | 4 | 2008 | 233 | 0.800 |
Why?
|
| Hospital Mortality | 6 | 2023 | 1025 | 0.780 |
Why?
|
| Decision Support Techniques | 3 | 2023 | 290 | 0.760 |
Why?
|
| Cross-Sectional Studies | 19 | 2023 | 3426 | 0.750 |
Why?
|
| Eligibility Determination | 4 | 2022 | 37 | 0.750 |
Why?
|
| Health Insurance Exchanges | 1 | 2021 | 3 | 0.750 |
Why?
|
| Diagnosis-Related Groups | 4 | 2010 | 28 | 0.740 |
Why?
|
| Healthcare Disparities | 8 | 2021 | 430 | 0.740 |
Why?
|
| Perioperative Period | 1 | 2021 | 50 | 0.730 |
Why?
|
| National Health Insurance, United States | 1 | 2020 | 3 | 0.710 |
Why?
|
| Colonoscopy | 4 | 2023 | 240 | 0.710 |
Why?
|
| Cancer Survivors | 4 | 2025 | 205 | 0.700 |
Why?
|
| Drug Prescriptions | 8 | 2020 | 221 | 0.700 |
Why?
|
| Sex Factors | 10 | 2024 | 1277 | 0.700 |
Why?
|
| Surgical Procedures, Operative | 2 | 2021 | 182 | 0.690 |
Why?
|
| Health Care Reform | 1 | 2020 | 50 | 0.690 |
Why?
|
| Employment | 2 | 2020 | 67 | 0.670 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2021 | 264 | 0.630 |
Why?
|
| Mindfulness | 3 | 2024 | 20 | 0.630 |
Why?
|
| Attitude of Health Personnel | 9 | 2020 | 672 | 0.630 |
Why?
|
| Work Performance | 1 | 2019 | 14 | 0.630 |
Why?
|
| Communication | 6 | 2020 | 515 | 0.620 |
Why?
|
| Adult | 47 | 2025 | 29394 | 0.620 |
Why?
|
| Motivation | 3 | 2019 | 313 | 0.610 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 51 | 0.600 |
Why?
|
| Hospital Costs | 5 | 2007 | 179 | 0.600 |
Why?
|
| Registries | 11 | 2021 | 1419 | 0.600 |
Why?
|
| Ambulatory Care Facilities | 4 | 2016 | 227 | 0.600 |
Why?
|
| Aspirin | 6 | 2020 | 224 | 0.590 |
Why?
|
| Reminder Systems | 2 | 2009 | 60 | 0.580 |
Why?
|
| Cardiology | 7 | 2019 | 501 | 0.580 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2016 | 847 | 0.580 |
Why?
|
| Fee-for-Service Plans | 4 | 2009 | 18 | 0.570 |
Why?
|
| Patient-Centered Care | 3 | 2019 | 224 | 0.570 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2023 | 1251 | 0.570 |
Why?
|
| Myocardial Ischemia | 9 | 2021 | 340 | 0.570 |
Why?
|
| Referral and Consultation | 3 | 2010 | 539 | 0.550 |
Why?
|
| Decision Support Systems, Clinical | 4 | 2023 | 171 | 0.550 |
Why?
|
| Retrospective Studies | 27 | 2024 | 16270 | 0.550 |
Why?
|
| Cardiac Catheterization | 6 | 2007 | 633 | 0.540 |
Why?
|
| Diagnostic Imaging | 2 | 2009 | 275 | 0.520 |
Why?
|
| Intensive Care, Neonatal | 2 | 2014 | 53 | 0.520 |
Why?
|
| Diffusion of Innovation | 2 | 2009 | 96 | 0.510 |
Why?
|
| Interprofessional Relations | 2 | 2014 | 144 | 0.500 |
Why?
|
| Electronic Health Records | 5 | 2024 | 723 | 0.490 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 1088 | 0.490 |
Why?
|
| Risk Assessment | 11 | 2021 | 3392 | 0.490 |
Why?
|
| Anticholesteremic Agents | 5 | 2019 | 234 | 0.480 |
Why?
|
| Depression | 5 | 2024 | 1244 | 0.480 |
Why?
|
| American Heart Association | 4 | 2019 | 319 | 0.470 |
Why?
|
| Peripheral Arterial Disease | 5 | 2020 | 284 | 0.470 |
Why?
|
| Blood Pressure | 7 | 2019 | 1330 | 0.460 |
Why?
|
| Age Factors | 10 | 2021 | 2810 | 0.460 |
Why?
|
| Research Report | 1 | 2014 | 75 | 0.460 |
Why?
|
| Diabetes Complications | 2 | 2016 | 198 | 0.450 |
Why?
|
| Clinical Competence | 7 | 2019 | 997 | 0.450 |
Why?
|
| Health Personnel | 2 | 2018 | 505 | 0.430 |
Why?
|
| Publishing | 1 | 2014 | 109 | 0.430 |
Why?
|
| Health Services | 3 | 2008 | 71 | 0.430 |
Why?
|
| Safety Management | 4 | 2012 | 112 | 0.430 |
Why?
|
| Cooperative Behavior | 4 | 2020 | 220 | 0.430 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2013 | 28 | 0.420 |
Why?
|
| Attitude to Health | 2 | 2005 | 257 | 0.420 |
Why?
|
| Data Collection | 6 | 2023 | 383 | 0.410 |
Why?
|
| Nursing Homes | 1 | 2013 | 95 | 0.410 |
Why?
|
| Dissent and Disputes | 2 | 2023 | 32 | 0.400 |
Why?
|
| Secondary Prevention | 4 | 2022 | 216 | 0.400 |
Why?
|
| Program Evaluation | 2 | 2015 | 447 | 0.400 |
Why?
|
| Problem Solving | 1 | 2012 | 63 | 0.400 |
Why?
|
| Occult Blood | 2 | 2009 | 33 | 0.400 |
Why?
|
| Ethics Committees, Research | 1 | 2012 | 32 | 0.390 |
Why?
|
| Colorectal Neoplasms | 5 | 2011 | 566 | 0.390 |
Why?
|
| Primary Prevention | 4 | 2023 | 167 | 0.390 |
Why?
|
| Databases, Factual | 7 | 2017 | 1178 | 0.380 |
Why?
|
| Adrenergic beta-Antagonists | 5 | 2018 | 241 | 0.380 |
Why?
|
| Medical Audit | 6 | 2016 | 99 | 0.380 |
Why?
|
| Aged, 80 and over | 17 | 2020 | 6484 | 0.380 |
Why?
|
| Coronary Angiography | 5 | 2007 | 427 | 0.380 |
Why?
|
| Lipoproteins | 2 | 2018 | 178 | 0.370 |
Why?
|
| Breast Neoplasms | 4 | 2025 | 2505 | 0.370 |
Why?
|
| Infant Mortality | 1 | 2012 | 173 | 0.370 |
Why?
|
| Clinical Pharmacy Information Systems | 2 | 2009 | 20 | 0.360 |
Why?
|
| Comorbidity | 9 | 2021 | 1527 | 0.360 |
Why?
|
| Financing, Government | 2 | 2009 | 30 | 0.360 |
Why?
|
| Risk Factors | 21 | 2021 | 10181 | 0.360 |
Why?
|
| Budgets | 2 | 2021 | 17 | 0.360 |
Why?
|
| Patient Admission | 4 | 2010 | 186 | 0.350 |
Why?
|
| Cohort Studies | 15 | 2021 | 4751 | 0.350 |
Why?
|
| Infant, Premature, Diseases | 1 | 2013 | 241 | 0.350 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2008 | 93 | 0.350 |
Why?
|
| Postoperative Complications | 2 | 2024 | 3066 | 0.340 |
Why?
|
| Cholesterol, HDL | 3 | 2019 | 350 | 0.330 |
Why?
|
| Internal Medicine | 4 | 2020 | 150 | 0.330 |
Why?
|
| Models, Statistical | 5 | 2013 | 471 | 0.330 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 133 | 0.330 |
Why?
|
| Socioeconomic Factors | 7 | 2020 | 872 | 0.320 |
Why?
|
| International Classification of Diseases | 1 | 2010 | 90 | 0.320 |
Why?
|
| Angioplasty, Balloon, Coronary | 5 | 2007 | 174 | 0.320 |
Why?
|
| Group Practice | 1 | 2009 | 11 | 0.320 |
Why?
|
| Health Care Rationing | 2 | 2007 | 58 | 0.320 |
Why?
|
| Odds Ratio | 9 | 2020 | 1250 | 0.310 |
Why?
|
| Economics, Hospital | 1 | 2008 | 7 | 0.310 |
Why?
|
| Predictive Value of Tests | 7 | 2019 | 2127 | 0.310 |
Why?
|
| Medical Order Entry Systems | 2 | 2010 | 101 | 0.310 |
Why?
|
| Medication Errors | 2 | 2009 | 188 | 0.310 |
Why?
|
| Medicine | 2 | 2010 | 97 | 0.310 |
Why?
|
| Drug Costs | 2 | 2019 | 60 | 0.310 |
Why?
|
| Prevalence | 5 | 2021 | 2442 | 0.300 |
Why?
|
| Ezetimibe | 3 | 2019 | 95 | 0.300 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2019 | 36 | 0.300 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 5125 | 0.300 |
Why?
|
| Patient Satisfaction | 4 | 2009 | 478 | 0.290 |
Why?
|
| Hospital Information Systems | 1 | 2008 | 44 | 0.290 |
Why?
|
| Time Factors | 12 | 2020 | 6285 | 0.290 |
Why?
|
| Health Status | 2 | 2007 | 374 | 0.290 |
Why?
|
| Coronary Artery Bypass | 6 | 2010 | 514 | 0.290 |
Why?
|
| Internet | 2 | 2020 | 383 | 0.290 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2007 | 33 | 0.280 |
Why?
|
| Behavioral Risk Factor Surveillance System | 6 | 2022 | 52 | 0.280 |
Why?
|
| Decision Theory | 1 | 2006 | 2 | 0.270 |
Why?
|
| Patient Transfer | 1 | 2007 | 103 | 0.270 |
Why?
|
| Antihypertensive Agents | 3 | 2018 | 398 | 0.260 |
Why?
|
| Child Health Services | 1 | 2007 | 87 | 0.260 |
Why?
|
| Hepatitis C | 1 | 2010 | 364 | 0.260 |
Why?
|
| Brain Ischemia | 2 | 2020 | 259 | 0.260 |
Why?
|
| Angioplasty | 1 | 2006 | 87 | 0.260 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2007 | 124 | 0.250 |
Why?
|
| Thrombolytic Therapy | 4 | 2016 | 204 | 0.250 |
Why?
|
| Community Health Centers | 1 | 2005 | 39 | 0.250 |
Why?
|
| Treatment Outcome | 16 | 2021 | 12315 | 0.250 |
Why?
|
| Medical Errors | 2 | 2007 | 155 | 0.240 |
Why?
|
| Elective Surgical Procedures | 1 | 2006 | 159 | 0.240 |
Why?
|
| Feedback | 2 | 2019 | 163 | 0.240 |
Why?
|
| Specialization | 1 | 2005 | 75 | 0.240 |
Why?
|
| Patient Selection | 4 | 2019 | 693 | 0.230 |
Why?
|
| Long-Term Care | 1 | 2005 | 70 | 0.230 |
Why?
|
| Faculty, Medical | 3 | 2020 | 262 | 0.230 |
Why?
|
| Adolescent | 11 | 2024 | 19301 | 0.230 |
Why?
|
| Young Adult | 7 | 2024 | 8969 | 0.230 |
Why?
|
| Algorithms | 2 | 2012 | 1614 | 0.230 |
Why?
|
| Medical Records | 2 | 2008 | 191 | 0.230 |
Why?
|
| Thiophenes | 2 | 2014 | 60 | 0.230 |
Why?
|
| Health Services Needs and Demand | 1 | 2005 | 174 | 0.230 |
Why?
|
| Longitudinal Studies | 4 | 2025 | 1322 | 0.220 |
Why?
|
| Clinical Decision-Making | 3 | 2020 | 267 | 0.220 |
Why?
|
| Hypoglycemic Agents | 4 | 2022 | 441 | 0.220 |
Why?
|
| Prescription Drugs | 2 | 2014 | 53 | 0.220 |
Why?
|
| Focus Groups | 3 | 2019 | 201 | 0.220 |
Why?
|
| Mentally Ill Persons | 1 | 2003 | 21 | 0.210 |
Why?
|
| Mass Screening | 1 | 2009 | 784 | 0.210 |
Why?
|
| Cardiology Service, Hospital | 1 | 2003 | 15 | 0.210 |
Why?
|
| Total Quality Management | 2 | 2004 | 24 | 0.210 |
Why?
|
| Surveys and Questionnaires | 8 | 2020 | 3724 | 0.200 |
Why?
|
| Piperazines | 2 | 2014 | 238 | 0.200 |
Why?
|
| Hospitals, Private | 2 | 1999 | 18 | 0.200 |
Why?
|
| Texas | 8 | 2019 | 3588 | 0.200 |
Why?
|
| Risk | 3 | 2012 | 750 | 0.200 |
Why?
|
| Pharmaceutical Preparations | 2 | 2022 | 79 | 0.200 |
Why?
|
| Blood Glucose | 2 | 2017 | 1128 | 0.200 |
Why?
|
| Smoking Cessation | 1 | 2004 | 197 | 0.200 |
Why?
|
| Discriminant Analysis | 1 | 2002 | 26 | 0.200 |
Why?
|
| Inpatients | 1 | 2006 | 499 | 0.200 |
Why?
|
| Risk Management | 3 | 1998 | 68 | 0.200 |
Why?
|
| Software | 1 | 2007 | 686 | 0.190 |
Why?
|
| Iatrogenic Disease | 3 | 1998 | 132 | 0.190 |
Why?
|
| Empirical Research | 1 | 2001 | 9 | 0.190 |
Why?
|
| Fibrinolytic Agents | 3 | 2016 | 199 | 0.190 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2023 | 113 | 0.190 |
Why?
|
| Meditation | 1 | 2021 | 17 | 0.190 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2023 | 148 | 0.180 |
Why?
|
| Federal Government | 1 | 2021 | 15 | 0.180 |
Why?
|
| Organizational Culture | 2 | 2012 | 95 | 0.180 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2006 | 451 | 0.180 |
Why?
|
| Patient Education as Topic | 4 | 2020 | 441 | 0.180 |
Why?
|
| Goals | 2 | 2011 | 128 | 0.180 |
Why?
|
| Reproducibility of Results | 4 | 2012 | 2868 | 0.180 |
Why?
|
| Hospital Departments | 1 | 2020 | 15 | 0.180 |
Why?
|
| Qualitative Research | 3 | 2020 | 548 | 0.180 |
Why?
|
| Geography | 3 | 2020 | 110 | 0.170 |
Why?
|
| Rheumatic Fever | 1 | 2020 | 18 | 0.170 |
Why?
|
| Cluster Analysis | 2 | 2013 | 400 | 0.170 |
Why?
|
| Fatigue | 1 | 2021 | 193 | 0.170 |
Why?
|
| Aging | 2 | 2025 | 1187 | 0.170 |
Why?
|
| Internship and Residency | 5 | 2011 | 1177 | 0.170 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2021 | 94 | 0.170 |
Why?
|
| Rivaroxaban | 1 | 2020 | 55 | 0.170 |
Why?
|
| Biomarkers | 9 | 2019 | 2989 | 0.170 |
Why?
|
| Pediatrics | 2 | 2020 | 1154 | 0.170 |
Why?
|
| Population Health | 1 | 2020 | 37 | 0.170 |
Why?
|
| Medical Staff, Hospital | 2 | 1998 | 92 | 0.170 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 64 | 0.170 |
Why?
|
| Infant, Newborn | 8 | 2014 | 8180 | 0.170 |
Why?
|
| Heart Failure | 4 | 2023 | 2277 | 0.170 |
Why?
|
| Arthritis | 2 | 2011 | 81 | 0.170 |
Why?
|
| Asthma | 1 | 2007 | 748 | 0.170 |
Why?
|
| Population Surveillance | 1 | 2022 | 389 | 0.160 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 123 | 0.160 |
Why?
|
| Patient Preference | 1 | 2020 | 118 | 0.160 |
Why?
|
| Echocardiography, Stress | 1 | 2019 | 14 | 0.160 |
Why?
|
| Cerebrovascular Disorders | 2 | 2018 | 122 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 511 | 0.160 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 83 | 0.160 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2019 | 57 | 0.160 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 79 | 0.160 |
Why?
|
| White Coat Hypertension | 1 | 2018 | 10 | 0.160 |
Why?
|
| Multivariate Analysis | 8 | 2021 | 1419 | 0.150 |
Why?
|
| Health Care Surveys | 4 | 2011 | 286 | 0.150 |
Why?
|
| Transcriptome | 1 | 2025 | 937 | 0.150 |
Why?
|
| Databases as Topic | 2 | 2008 | 71 | 0.150 |
Why?
|
| Health Services Misuse | 1 | 1998 | 26 | 0.150 |
Why?
|
| Physicians, Family | 1 | 1998 | 37 | 0.150 |
Why?
|
| Clinical Medicine | 1 | 1998 | 21 | 0.150 |
Why?
|
| Pandemics | 2 | 2023 | 1105 | 0.150 |
Why?
|
| Societies, Medical | 3 | 2015 | 687 | 0.150 |
Why?
|
| Thinness | 1 | 2019 | 70 | 0.150 |
Why?
|
| Decision Making | 3 | 2003 | 654 | 0.150 |
Why?
|
| Interviews as Topic | 2 | 2017 | 377 | 0.150 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2019 | 79 | 0.150 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 2034 | 0.150 |
Why?
|
| Hospitals, Teaching | 4 | 2002 | 105 | 0.150 |
Why?
|
| Exercise Test | 1 | 2019 | 250 | 0.150 |
Why?
|
| Health Care Costs | 3 | 2021 | 370 | 0.140 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 188 | 0.140 |
Why?
|
| Diabetic Nephropathies | 1 | 2018 | 112 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 365 | 0.140 |
Why?
|
| Research Personnel | 2 | 2012 | 118 | 0.140 |
Why?
|
| Education, Medical, Continuing | 2 | 2016 | 138 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 1460 | 0.140 |
Why?
|
| Radiology | 2 | 2009 | 106 | 0.140 |
Why?
|
| Leadership | 1 | 2019 | 228 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 314 | 0.130 |
Why?
|
| Chronic Disease | 2 | 2012 | 1190 | 0.130 |
Why?
|
| Models, Theoretical | 3 | 2016 | 358 | 0.130 |
Why?
|
| Mental Disorders | 2 | 2003 | 824 | 0.130 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 459 | 0.130 |
Why?
|
| Formative Feedback | 1 | 2016 | 30 | 0.130 |
Why?
|
| Confidence Intervals | 2 | 2015 | 283 | 0.130 |
Why?
|
| Inservice Training | 1 | 2016 | 55 | 0.120 |
Why?
|
| Drug Utilization | 3 | 2020 | 162 | 0.120 |
Why?
|
| Health Facilities | 2 | 2018 | 59 | 0.120 |
Why?
|
| Bayes Theorem | 2 | 2007 | 282 | 0.120 |
Why?
|
| Physician-Patient Relations | 3 | 2005 | 426 | 0.120 |
Why?
|
| Amino Acids | 1 | 2018 | 663 | 0.120 |
Why?
|
| Regression Analysis | 2 | 2007 | 775 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2015 | 6082 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 247 | 0.120 |
Why?
|
| Incidence | 5 | 2021 | 3093 | 0.120 |
Why?
|
| Accident Prevention | 1 | 1994 | 9 | 0.120 |
Why?
|
| Malpractice | 2 | 2007 | 55 | 0.120 |
Why?
|
| Simvastatin | 1 | 2015 | 76 | 0.120 |
Why?
|
| Benchmarking | 2 | 2013 | 134 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 187 | 0.120 |
Why?
|
| Policy Making | 2 | 2009 | 57 | 0.120 |
Why?
|
| Smoking | 1 | 2020 | 1037 | 0.120 |
Why?
|
| Systems Analysis | 2 | 2006 | 15 | 0.120 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2016 | 109 | 0.120 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 631 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 170 | 0.110 |
Why?
|
| Myocardial Revascularization | 2 | 2006 | 100 | 0.110 |
Why?
|
| Outpatients | 1 | 2016 | 255 | 0.110 |
Why?
|
| Professional Review Organizations | 1 | 2013 | 1 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2020 | 721 | 0.110 |
Why?
|
| Sex Distribution | 1 | 2014 | 300 | 0.110 |
Why?
|
| Systems Integration | 2 | 2004 | 27 | 0.110 |
Why?
|
| Health Maintenance Organizations | 3 | 2009 | 22 | 0.110 |
Why?
|
| Needs Assessment | 2 | 2005 | 175 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2011 | 598 | 0.110 |
Why?
|
| Delphi Technique | 2 | 2012 | 210 | 0.100 |
Why?
|
| Random Allocation | 3 | 2011 | 436 | 0.100 |
Why?
|
| Neoplasms | 1 | 2007 | 2784 | 0.100 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2016 | 237 | 0.100 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 224 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2019 | 1556 | 0.100 |
Why?
|
| California | 1 | 2013 | 128 | 0.100 |
Why?
|
| Triglycerides | 2 | 2012 | 564 | 0.100 |
Why?
|
| Education, Medical, Graduate | 2 | 2016 | 515 | 0.100 |
Why?
|
| Acute Coronary Syndrome | 1 | 2015 | 209 | 0.100 |
Why?
|
| Factor Analysis, Statistical | 1 | 2013 | 239 | 0.100 |
Why?
|
| Research Support as Topic | 2 | 2020 | 63 | 0.100 |
Why?
|
| Disease Management | 2 | 2017 | 521 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2012 | 53 | 0.100 |
Why?
|
| Hypotension | 1 | 2013 | 181 | 0.100 |
Why?
|
| Information Dissemination | 2 | 2018 | 185 | 0.090 |
Why?
|
| Sample Size | 1 | 2011 | 86 | 0.090 |
Why?
|
| Neonatology | 1 | 2012 | 51 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1017 | 0.090 |
Why?
|
| Professional Practice Gaps | 2 | 2023 | 15 | 0.090 |
Why?
|
| Observer Variation | 1 | 2012 | 299 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2003 | 221 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2012 | 225 | 0.090 |
Why?
|
| Boston | 5 | 1998 | 110 | 0.090 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 175 | 0.090 |
Why?
|
| Least-Squares Analysis | 1 | 2010 | 30 | 0.090 |
Why?
|
| Reference Values | 2 | 2011 | 710 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2010 | 2896 | 0.090 |
Why?
|
| Patient Care Planning | 1 | 2011 | 122 | 0.090 |
Why?
|
| Viremia | 1 | 2010 | 128 | 0.080 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2009 | 10 | 0.080 |
Why?
|
| Linear Models | 2 | 2010 | 672 | 0.080 |
Why?
|
| Models, Psychological | 1 | 2010 | 138 | 0.080 |
Why?
|
| Medicare Part D | 1 | 2009 | 17 | 0.080 |
Why?
|
| Travel | 1 | 2010 | 116 | 0.080 |
Why?
|
| Choice Behavior | 1 | 2010 | 131 | 0.080 |
Why?
|
| Hepacivirus | 1 | 2010 | 241 | 0.080 |
Why?
|
| Pharmaceutical Services | 1 | 2009 | 35 | 0.080 |
Why?
|
| Delayed Diagnosis | 1 | 2010 | 125 | 0.080 |
Why?
|
| Hospitals, Urban | 3 | 1998 | 97 | 0.080 |
Why?
|
| Hospital Bed Capacity, 500 and over | 3 | 1998 | 15 | 0.080 |
Why?
|
| Multiple Organ Failure | 1 | 2010 | 141 | 0.080 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2010 | 1112 | 0.070 |
Why?
|
| Family Practice | 2 | 2011 | 90 | 0.070 |
Why?
|
| Hospitalization | 2 | 2007 | 1775 | 0.070 |
Why?
|
| Biomedical Technology | 1 | 2008 | 36 | 0.070 |
Why?
|
| Insurance Claim Review | 1 | 2007 | 27 | 0.070 |
Why?
|
| Cost Control | 1 | 2007 | 24 | 0.070 |
Why?
|
| Prognosis | 2 | 2014 | 4572 | 0.070 |
Why?
|
| Case-Control Studies | 4 | 2021 | 3269 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2010 | 236 | 0.070 |
Why?
|
| Estrogen Replacement Therapy | 2 | 1998 | 42 | 0.070 |
Why?
|
| Models, Econometric | 1 | 2007 | 9 | 0.070 |
Why?
|
| Ohio | 1 | 2007 | 86 | 0.070 |
Why?
|
| Obesity | 1 | 2019 | 2267 | 0.070 |
Why?
|
| Chi-Square Distribution | 3 | 2010 | 582 | 0.070 |
Why?
|
| Probability | 1 | 2007 | 323 | 0.070 |
Why?
|
| Cost of Illness | 2 | 2006 | 247 | 0.070 |
Why?
|
| Health Policy | 1 | 2009 | 212 | 0.070 |
Why?
|
| Women's Health | 1 | 2008 | 132 | 0.070 |
Why?
|
| Aviation | 1 | 2006 | 8 | 0.070 |
Why?
|
| Statistical Distributions | 1 | 2006 | 3 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 324 | 0.070 |
Why?
|
| Ergonomics | 1 | 2006 | 20 | 0.070 |
Why?
|
| Health Education | 1 | 2008 | 222 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2006 | 151 | 0.060 |
Why?
|
| Cardiac Care Facilities | 1 | 2006 | 8 | 0.060 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2010 | 479 | 0.060 |
Why?
|
| Nephrology | 1 | 2007 | 145 | 0.060 |
Why?
|
| Economics, Medical | 1 | 2005 | 7 | 0.060 |
Why?
|
| Angina, Unstable | 1 | 2006 | 52 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 1687 | 0.060 |
Why?
|
| Insurance, Health | 1 | 2006 | 138 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2010 | 746 | 0.060 |
Why?
|
| Cross-Cultural Comparison | 1 | 2005 | 59 | 0.060 |
Why?
|
| Rumination, Cognitive | 1 | 2024 | 1 | 0.060 |
Why?
|
| Recovery of Function | 1 | 2007 | 443 | 0.060 |
Why?
|
| Utilization Review | 1 | 2004 | 39 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 1158 | 0.060 |
Why?
|
| Quality of Life | 2 | 2021 | 1944 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2025 | 100 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 1090 | 0.060 |
Why?
|
| Infant, Premature | 1 | 2010 | 814 | 0.060 |
Why?
|
| Staff Development | 1 | 2004 | 44 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2007 | 762 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2006 | 1017 | 0.060 |
Why?
|
| Psychometrics | 2 | 2012 | 675 | 0.050 |
Why?
|
| Cellular Senescence | 1 | 2025 | 162 | 0.050 |
Why?
|
| Regional Medical Programs | 1 | 2003 | 16 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1892 | 0.050 |
Why?
|
| Virginia | 1 | 2003 | 20 | 0.050 |
Why?
|
| Awards and Prizes | 1 | 2004 | 64 | 0.050 |
Why?
|
| Morbidity | 1 | 2024 | 244 | 0.050 |
Why?
|
| Patient Discharge | 3 | 2010 | 496 | 0.050 |
Why?
|
| General Surgery | 1 | 2005 | 204 | 0.050 |
Why?
|
| Career Choice | 1 | 2004 | 143 | 0.050 |
Why?
|
| Models, Organizational | 1 | 2003 | 39 | 0.050 |
Why?
|
| Attitude to Computers | 1 | 2003 | 49 | 0.050 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2003 | 65 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2007 | 968 | 0.050 |
Why?
|
| Race Relations | 1 | 2002 | 1 | 0.050 |
Why?
|
| Bias | 1 | 2003 | 131 | 0.050 |
Why?
|
| Pyridones | 1 | 2023 | 112 | 0.050 |
Why?
|
| Costs and Cost Analysis | 3 | 2017 | 164 | 0.050 |
Why?
|
| Personnel, Hospital | 2 | 2012 | 34 | 0.050 |
Why?
|
| DNA Damage | 1 | 2025 | 515 | 0.050 |
Why?
|
| Occupational Health | 2 | 2012 | 44 | 0.050 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 63 | 0.050 |
Why?
|
| Survival Rate | 1 | 2006 | 2028 | 0.050 |
Why?
|
| Cognition | 1 | 2006 | 730 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 491 | 0.050 |
Why?
|
| Survivorship | 1 | 2021 | 37 | 0.050 |
Why?
|
| Matched-Pair Analysis | 1 | 2000 | 28 | 0.050 |
Why?
|
| Minority Groups | 1 | 2003 | 251 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2022 | 138 | 0.040 |
Why?
|
| Epidemiology | 1 | 2020 | 9 | 0.040 |
Why?
|
| Nursing | 1 | 2020 | 11 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 877 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 49 | 0.040 |
Why?
|
| Hospitals, Low-Volume | 1 | 2019 | 30 | 0.040 |
Why?
|
| Cigarette Smoking | 1 | 2020 | 59 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 581 | 0.040 |
Why?
|
| Hospitals, High-Volume | 1 | 2019 | 35 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2020 | 103 | 0.040 |
Why?
|
| Educational Status | 1 | 2020 | 271 | 0.040 |
Why?
|
| Personnel Turnover | 1 | 2019 | 9 | 0.040 |
Why?
|
| Social Networking | 1 | 2019 | 17 | 0.040 |
Why?
|
| Medical Informatics | 1 | 2020 | 108 | 0.040 |
Why?
|
| Models, Economic | 1 | 2019 | 51 | 0.040 |
Why?
|
| Self Report | 1 | 2022 | 520 | 0.040 |
Why?
|
| New England | 1 | 1998 | 12 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 306 | 0.040 |
Why?
|
| Research | 1 | 2020 | 263 | 0.040 |
Why?
|
| Proprotein Convertase 9 | 1 | 2019 | 69 | 0.040 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 1998 | 5 | 0.040 |
Why?
|
| Sentinel Surveillance | 1 | 1998 | 19 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 275 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 1998 | 142 | 0.040 |
Why?
|
| APACHE | 1 | 1998 | 53 | 0.040 |
Why?
|
| Noncommunicable Diseases | 1 | 2018 | 16 | 0.040 |
Why?
|
| Prostatic Hyperplasia | 1 | 1998 | 115 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 1998 | 256 | 0.040 |
Why?
|
| Osteoporosis | 1 | 1998 | 116 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 883 | 0.040 |
Why?
|
| Emergencies | 1 | 1998 | 173 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2002 | 490 | 0.030 |
Why?
|
| Physician's Role | 1 | 1998 | 164 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2020 | 464 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 355 | 0.030 |
Why?
|
| Hospital Charges | 1 | 1997 | 61 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 1996 | 112 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 1998 | 340 | 0.030 |
Why?
|
| Stroke | 2 | 2020 | 977 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 701 | 0.030 |
Why?
|
| Mammography | 1 | 1996 | 114 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 140 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 186 | 0.030 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 359 | 0.030 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 375 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 1994 | 39 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2016 | 130 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 438 | 0.030 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2014 | 22 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1490 | 0.030 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2014 | 46 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 1994 | 254 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 1218 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 502 | 0.030 |
Why?
|
| Cross Infection | 1 | 2016 | 329 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2016 | 588 | 0.020 |
Why?
|
| Job Satisfaction | 1 | 2011 | 78 | 0.020 |
Why?
|
| Length of Stay | 1 | 1997 | 1309 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 2011 | 75 | 0.020 |
Why?
|
| Child | 2 | 2010 | 24439 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 1106 | 0.020 |
Why?
|
| Vital Signs | 1 | 2010 | 19 | 0.020 |
Why?
|
| Heart Valves | 1 | 2010 | 52 | 0.020 |
Why?
|
| Acute Disease | 2 | 2006 | 1108 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2009 | 111 | 0.020 |
Why?
|
| Endocrinology | 1 | 2011 | 136 | 0.020 |
Why?
|
| Medicare Part C | 1 | 2009 | 37 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 425 | 0.020 |
Why?
|
| Comprehension | 1 | 2008 | 75 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 539 | 0.020 |
Why?
|
| Insurance, Liability | 1 | 2007 | 7 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2010 | 196 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 126 | 0.020 |
Why?
|
| Weight Gain | 1 | 2010 | 405 | 0.020 |
Why?
|
| HIV Infections | 1 | 1998 | 1891 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2011 | 557 | 0.020 |
Why?
|
| Neck Pain | 1 | 2006 | 19 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2009 | 359 | 0.020 |
Why?
|
| Spinal Cord Compression | 1 | 2006 | 31 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2006 | 193 | 0.020 |
Why?
|
| Accreditation | 1 | 2005 | 87 | 0.010 |
Why?
|
| Training Support | 1 | 2004 | 17 | 0.010 |
Why?
|
| Hospitals, University | 2 | 1995 | 97 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2005 | 197 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2004 | 133 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2010 | 854 | 0.010 |
Why?
|
| Syndrome | 1 | 2006 | 1118 | 0.010 |
Why?
|
| Mentors | 1 | 2004 | 143 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2002 | 56 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 1600 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2004 | 277 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2005 | 578 | 0.010 |
Why?
|
| Pharmacies | 1 | 1998 | 13 | 0.010 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 1998 | 49 | 0.010 |
Why?
|
| Drug Therapy | 1 | 1997 | 85 | 0.010 |
Why?
|
| Patient Readmission | 1 | 1995 | 383 | 0.010 |
Why?
|